Proteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops novel therapeutics to treat cystic fibrosis and other diseases caused by an imbalance in the proteostasis network. Its lead product candidate is PTI-428, an orally bioavailable cystic fibrosis transmembrane conductance regulator modulator belonging to the amplifier class, which is in Phase II study. The company is also involved in developing PTI-801, a corrector molecule; and PTI-808, a potentiator molecule that have been completed Phase I Study. It has a collaboration agreement with Astellas Pharma Inc. Astellas Pharma, Inc. to research and identify therapies targeting the UPR pathway. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. Proteostasis Therapeutics, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PTI
CUSIPN/A
Phone617-225-0096
Debt
Debt-to-Equity RatioN/A
Current Ratio6.70
Quick Ratio6.70
Price-To-Earnings
Trailing P/E Ratio-1.06
Forward P/E Ratio-1.28
P/E GrowthN/A
Sales & Book Value
Annual Sales$5.34 million
Price / Sales17.73
Cash FlowN/A
Price / CashN/A
Book Value$2.08 per share
Price / Book1.24
Profitability
EPS (Most Recent Fiscal Year)($2.34)
Net Income$-59,430,000.00
Net Margins-1,086.77%
Return on Equity-96.44%
Return on Assets-68.03%
Miscellaneous
Employees52
Outstanding Shares36,700,000
Market Cap$89.54 million
Proteostasis Therapeutics (NASDAQ:PTI) Frequently Asked Questions
What is Proteostasis Therapeutics' stock symbol?
Proteostasis Therapeutics trades on the NASDAQ under the ticker symbol "PTI."
How were Proteostasis Therapeutics' earnings last quarter?
Proteostasis Therapeutics Inc (NASDAQ:PTI) announced its quarterly earnings data on Wednesday, August, 8th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.39) by $0.04. Proteostasis Therapeutics had a negative net margin of 1,086.77% and a negative return on equity of 96.44%. View Proteostasis Therapeutics' Earnings History.
When is Proteostasis Therapeutics' next earnings date?
What price target have analysts set for PTI?
3 Wall Street analysts have issued twelve-month price targets for Proteostasis Therapeutics' stock. Their predictions range from $5.00 to $25.00. On average, they anticipate Proteostasis Therapeutics' stock price to reach $13.25 in the next year. This suggests a possible upside of 413.6% from the stock's current price. View Analyst Price Targets for Proteostasis Therapeutics.
What is the consensus analysts' recommendation for Proteostasis Therapeutics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Proteostasis Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Proteostasis Therapeutics.
Who are some of Proteostasis Therapeutics' key competitors?
Some companies that are related to Proteostasis Therapeutics include Keryx Biopharmaceuticals (KERX), American Brivision (Holding) (ABVC), Clementia Pharmaceuticals (CMTA), AVEO Pharmaceuticals (AVEO), Synlogic (SYBX), Sienna Biopharmaceuticals (SNNA), ProMetic Life Sciences (PFSCF), MEI Pharma (MEIP), Corium International (CORI), Concert Pharmaceuticals (CNCE), Marinus Pharmaceuticals (MRNS), Selecta Biosciences (SELB), Catalyst Pharmaceuticals (CPRX), Innate Pharma (IPHYF) and Seres Therapeutics (MCRB).
Who are Proteostasis Therapeutics' key executives?
Proteostasis Therapeutics' management team includes the folowing people:
- Ms. Meenu Chhabra, Pres, CEO & Director (Age 46)
- Dr. Benito Munoz, Chief Scientific Officer (Age 56)
- Dr. Po-Shun Lee, Exec. VP & Chief Medical Officer (Age 49)
- Dr. Marija Zecevic, Chief Operating Officer (Age 44)
- Ms. Janet L. Smart, VP of Intellectual Property & Legal Affairs (Age 61)
When did Proteostasis Therapeutics IPO?
(PTI) raised $51 million in an initial public offering (IPO) on Thursday, February 11th 2016. The company issued 3,900,000 shares at $12.00-$14.00 per share. Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Baird and H.C. Wainwright & Co. were co-managers.
Has Proteostasis Therapeutics been receiving favorable news coverage?
Media stories about PTI stock have been trending somewhat positive recently, Accern reports. The research firm identifies negative and positive news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Proteostasis Therapeutics earned a news impact score of 0.18 on Accern's scale. They also gave media coverage about the company an impact score of 46.57 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. View Recent Headlines for Proteostasis Therapeutics.
Who are Proteostasis Therapeutics' major shareholders?
Proteostasis Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Jennison Associates LLC (10.15%), BlackRock Inc. (5.01%), RTW Investments LP (2.94%), Bailard Inc. (1.61%), Northern Trust Corp (0.73%) and Bank of New York Mellon Corp (0.17%). Company insiders that own Proteostasis Therapeutics stock include Cormorant Asset Management, Ll, Enterprise Associates 12 New, Fmr Llc, Franklin M Berger and Meenu Chhabra. View Institutional Ownership Trends for Proteostasis Therapeutics.
Which institutional investors are selling Proteostasis Therapeutics stock?
Which institutional investors are buying Proteostasis Therapeutics stock?
PTI stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Northern Trust Corp, Bailard Inc., Acadian Asset Management LLC, Bank of New York Mellon Corp, Bank of New York Mellon Corp, Jennison Associates LLC and Schwab Charles Investment Management Inc.. Company insiders that have bought Proteostasis Therapeutics stock in the last two years include Cormorant Asset Management, Ll, Enterprise Associates 12 New, Franklin M Berger and Meenu Chhabra. View Insider Buying and Selling for Proteostasis Therapeutics.
How do I buy shares of Proteostasis Therapeutics?
Shares of PTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Proteostasis Therapeutics' stock price today?
One share of PTI stock can currently be purchased for approximately $2.58.
How big of a company is Proteostasis Therapeutics?
Proteostasis Therapeutics has a market capitalization of $89.54 million and generates $5.34 million in revenue each year. The company earns $-59,430,000.00 in net income (profit) each year or ($2.34) on an earnings per share basis. Proteostasis Therapeutics employs 52 workers across the globe.
How can I contact Proteostasis Therapeutics?
Proteostasis Therapeutics' mailing address is 80 GUEST STREET 5TH FLOOR, BOSTON MA, 02135. The company can be reached via phone at 617-225-0096 or via email at [email protected]
MarketBeat Community Rating for Proteostasis Therapeutics (NASDAQ PTI)
MarketBeat's community ratings are surveys of what our community members think about Proteostasis Therapeutics and other stocks. Vote "Outperform" if you believe PTI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTI will underperform the S&P 500 over the long term. You may vote once every thirty days.
